This article revise the evidence of four new drugs. Naxolegol, a new opioid antagonist to the opioid-induced constipated treatment; opicapona, a new inhibitor of catechol-O-methyltransferase to the Parkinson disease treatment, and finally mepolizumab and reslizumab, two new monoclonal antibodies to the treatment of severe eosinophilic asthma.
New drugs; Naloxegol; Opicapona; Mepolizumab; Reslizumab
Robert L, Diego L. Novetats terapèutiques 2017. Butll Inf Ter. 2017 Des;28(10):75-81.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/3558
This item appears in following collections
- DS - Articles científics 
The following license files are associated with this item: